News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website



Posted on: 10/19/2007

MEDIA RELEASE (Embargoed until Midnight Saturday 20 October 2007)
Research commissioned by the International Brain Tumour Alliance (IBTA) has identified that annually at least 200,000 people worldwide develop a primary malignant brain tumour, which is one of the most lethal of all cancers. (IBTA website: )
It further identified that the incidence of primary malignant brain tumours is 3.7 per 100,000 each year for males and 2.6 per 100,000 per annum for females.
No one has yet established why men are more susceptible to developing these brain tumours.
(Further statistical information is available at this page on the IBTA website: )
The research was released at the commencement of the inaugural International Brain Tumour Awareness Week which is being held during 21-27 October.
The IBTA is an advocacy group that brings together brain tumour patients, their caregivers, scientists, clinicians, and commercial companies, with an interest in brain tumours.
IBTA Chair Denis Strangman from Canberra, Australia, who lost his wife several years ago to a glioblastoma brain tumour, said that the statistical estimates while invaluable, were very conservative and probably an underestimation because of inadequate cancer statistical collection resources in some countries.
There are also many thousands of people who develop so-called benign brain tumours that can also be lethal, and there are also hundreds of thousands of people who develop brain metastases as a result of a cancer elsewhere in the body. The overall impact and cost is almost incalculable but it is a very devastating disease, he said.
Meanwhile, one of the world's leading specialists in brain tumour research has called for greater attention to be given to brain tumours.
Professor M.J. van den Bent of the Netherlands, who was a member of the international team that identified the advantages of combining radiation therapy with the drug temozolomide for glioblastoma brain tumours, says that better treatments for brain tumours are urgently needed and also an increased awareness of the effects of this cancer on the person and their relatives.

"Most primary brain tumours have a very poor prognosis, and many of the affected patients are young. Apart from the shortened life, these patients suffer from a variety of signs and symptoms that have an enormous impact on their quality of life.

"In particular, the presence of cognitive deficits, memory disturbances, personality changes and other neurological deficits, often interfere with daily functioning and prevent these patients from leading a normal active life; and because of these cognitive deficits and personality changes the relatives of these patients suffer as well.

"Better treatments are urgently needed and also an increased awareness of what these tumours cause for patients that look healthy but who nonetheless often suffer from a dramatic loss of function, and what consequences this has for their relatives.

"I sincerely hope that the International Brain Tumour Awareness Week increases the attention given to this horrible disease. Despite recent advances, a lot has still to be done. Only joint efforts will help us to improve the outcome for this gruesome disease," Professor van den Bent said.
Background to the Awareness Week:
The inaugural International Brain Tumour Awareness Week is being held during 21-27 October 2007 and has been supported by almost 100 patient, professional, scientific and commercial organisations from 23 different countries. The main activity has been the Walk Around the World For Brain Tumours whereby people undertake sponsored walks for local brain tumour research and support purposes and donate the mileage to the IBTA to achieve a target of 40,000 kms representing once around the Earth at the Equator. 29 such walks have already taken place and the target is likely to be greatly exceeded, with a further 41 walks planned during the Awareness Week. A media release about the World Walk will be issued during the Week. Scientific meetings, picnics and outings for patients and caregivers, and patient information meetings will also take place during the Week. The project has been supported by undirected grants from Schering-Plough, Lilly Oncology, Ark Therapeutics, NovoCure, Antisense Pharma, and Neuroendoscopy.
Brain tumour patient support organisations:
There are hyper-links to 49 national and local brain tumour organisations on the right-hand column of the homepage for the IBTA at These organisations can provide information and comment about local situations.
        There are over 120 different types of brain tumour.
        There are two main categories of brain tumours: primary and metastatic.  Primary brain tumours can either be malignant (of varying degrees of aggressiveness) or non-malignant (so-called benign).
        Tumours are diagnosed and then classified according to the World Health Organisation (WHO) grading system which ranges from Grade I brain tumours (slow growing, least malignant) to Grade IV brain tumours (rapidly growing and highly malignant)
        The causes of brain tumours are, as yet, largely unknown.
        Brain tumours know no boundaries.  They occur in people of all ages, from very tiny babies to the elderly, male and female, and across all cultural groups around the world.
        The cancers that most commonly metastasize to the brain are lung and breast.
        What is needed: Research into the causes of, and treatments for, brain tumours is seriously under-funded.  Better support is needed for sufferers.  Equitable access to promising new therapies is another area which needs much work.  Understanding the signs and symptoms of brain tumours, and improved availability to a wider range of vital support services including psycho-social support, rehabilitation and palliative care, and access to neuro-oncology care coordinators, are additional goals which most people in the brain tumour community campaign for.

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557